Classifications

• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
  • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
  • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/765—Polymers containing oxygen
  • A61K31/77—Polymers containing oxygen of oxiranes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/04—Artificial tears; Irrigation solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
  • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
  • C11D1/008—Polymeric surface-active agents
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
  • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
  • C11D3/16—Organic compounds
  • C11D3/20—Organic compounds containing oxygen
  • C11D3/22—Carbohydrates or derivatives thereof
  • C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• I he present invention relates generally to ethyleneoxide butyleneoxide block copolymer compositions and specifically to ethyleneoxide butyleneoxide block copolymer compositions comprising a galactomannan such as guar or a guar derivative.
• polymeric ingredients are typically used in suspension compositions as physical stability aids, helping to keep the insoluble ingredients suspended or easily rediapersibk. Polymers also impart desirable viscoeiastk and Theological characteristics to compositions of which they are a parl. Many polymers have been used in topically administrabie ophthalmic compositions. Included among these are cellulosic polymers, such as hydroxypropyl methylcellulose. hydroxyethy! cellulose, and ethylhydroxyediyl cellulose. Also included are synthetic polymers, such as carboxyvinyl polymers and polyvinyl alcohol. Still others include polysaccharides such as xanthan gum, guar gum. and dextran.
• Combinations of polymers have also been used in ophthalmic compositions. Certain combinations of polymers are known to provide synergistic effects on viscosity and, in some cases, even a phase transition from a liquid to a gel. For example.
• U.S. Pat. No. 4,136, ⁇ 73 discloses ophthalmic compositions containing a combination of xanthan gum and locust bean gurn.
• the present invention is directed in certain embodiments to ophthalmic compositions comprising an ethyleneoxidc buty ⁇ eneoxide (EX)-BO) block copolymer of the formula (EO) m (BO) n and a galactomannan such as guar or a giiar derivative.
• EX ethyleneoxidc buty ⁇ eneoxide
• BO ethyleneoxide m
• a galactomannan such as guar or a giiar derivative.
• the present inventors have unexpectedly discovered that ethyleneoxide biuyieneoxide Mock copolymers interact with galactomannans in aqueous solution.
• Aqueous compositions comprising EO-BO copolymers are generally Newtonian in behavior, and EO-BO copolymer contributes little to the viscosity of such composition at lower concentrations.
• the present invention have a synergistic increase in viscosity relative to compositions comprising gaiactoman ⁇ an or EO-BO alone.
• the gaiact ⁇ raannan and EO-BO compositions of the present invention have desirable viscoelastic and interfacial properties that make them well suited for ophthalmic applications, and in particular for contact lens disinfection and reweUmg.
• Ethyleneoxide b ⁇ tyieneoxide block copolymers are very hydrophobic amphiphiles in aqueous solutions. At an air-water interface these nonionic surfactants form elastic layers that can provide a cushioning effect for contact lenses when used in ophthalmic solutions. Furthermore, by modifying the hydrophobicity (changing the butyleneoxide unit) of EO-BO block copolymers in solution, advantageous changes in the elasticity of such solutions can occur. in a preferred embodiment, the compositions of.
• the present invention comprise a ethyleneoxide butyleneoxide block copolymer of the formula (EO) m (BO) n where m is an integer having an average value of 10 to 1000 and n is an integer having an average value of 5 to 1000 and where the galactomannan is a guar derivative such as hydroxypropyl guar, native guar, or hydroxypropyl guar galactomannan.
• Embodiments of the present invention also comprise the use of compositions comprising ethyleneoxide butyleneoxide block copolymer and a galactomannan in contact lens disinfection solutions, dry eye and artificial tear compositions.
• the present invention is also directed to methods of using these compositions to treat various ophthalmic disorders including dry eye, glaucoma, ocular hypertension, infection, allergy and inflammation.
• the foregoing brief summary broadly describes the features and technical advantages of certain embodiments of the present invention. Additional features and technical advantages will be described in the detailed description of the invention thai follows. Novel features which are believed to be characteristic of the invention will be better understood from the detailed description of the invention.
• FIGURE 1 shows the amplitude sweep for various HO-BO compositions.
• FIGURES 2a-2e show steady state flow curves for EO-BO and HP-guar compositions.
• FIGURES 3a-3e show stress sweep curves for HO-BO and HP-guar compositions of TABLE 2.
• FIGURES 4a-4e show frequency sweep curves for EO-BO ami HP-guar compositions of TABLE 2.
• FIGURES 5a-5d show extcnsional rheology curves for EO-BO and HP-guar compositions of TABLE 2.
• FIGURES 6a- ⁇ b are amplitude sweep and frequency sweep curves for EO-BO and EO-BO/HP-guar compositions.
• FIGURES 7a and 7b are bar charts summarizing experiments examining the ability of EO-BO compositions of the present invention to prevent the uptake of a polar iipid (FJTC-DHPE.
• FIGURE 8 is a bar chart showing the amount remaining of a non-polar lipid
• NBD-choiesterol on various silicon hydroge! lenses after treatment with compositions containing EO-BC) and HP-guar.
• FIGURES 9a-9d demonstrate the cleaning efficacy of a EO-BO composition of the present invention compared to vehicle.
• the present, invention is directed in certain embodiments to ophthalmic compositions comprising an ethyleneoxide hutyleneoxide (EO-BO) block copolymer and a galactomannan such as guar or a guar derivative.
• EO-BO ethyleneoxide hutyleneoxide
• galactomannan such as guar or a guar derivative.
• the ethyleneoxide butyleneoxide block copolymers of these compositions have the following general formula:
• the block copolymers of the present invention are those that include a poly(oxyethyle»e) block as the hydrophilic component and a poiy(oxybutylene) block as the hydrophobic component. These may be in form of a di-block copolymer, denoted as EO BO, a tri-bioek copolymer, represented as EO- BO-HO or BO-EO-BO, or other block-type configurations. Unless expressly indicated to the contrary, all references to "BO-BO block copolymers" herein include all of the foregoing forms.
• compositions of the present invention generally comprise EO-BO copolymer at a concentration of 0.001 to 1.0% ⁇ v/v.
• compositions of the present invention comprise EO-BO copolymer at a concentration of 0.01 to 0.1% w/v.
• EO-BO di-block copolymers of the following general formula are particularly preferred: wherein R is selected from the group consisting of hydrogen, methyl, ethyl, propyl and butyl; rn is an integer having an average value of IO to 1000; and n is an integer having an average value of 5 to H)OO.
• the EO-BO block copolymers utilized in the present invention have a molecular weight in the range of 1 ,000 to about 100.000 Daltons: and more preferably in the range of 1 ,000 to about 15.000 Daltons. Maintaining a proper hydrophi ⁇ c-lipophiiic balance (HLB) imparts certain properties to the IEO-BO block co-polymer compositions of the present invention.
• HLB hydrophi ⁇ c-lipophiiic balance
• the HLB of the block copolymers utilized in the compositions of the present invention is directly related to the solubility, surface wettability, and interfaciai surface activity properties of the compositions of the present invention.
• the BO portion of the block copolymer of formula (I) above is hydrophobic and is primarily responsible for the wettability properties of the compositions described herein.
• the EO portion of the copolymer provides the compositions with hydrophilic properties, but more importantly, it is this portion of the co-polymer that determines the aqueous solubility of the copolymers.
• sol ubil? zing agents in the compositions of the present invention, in which case lhe ratio of the EO to BO segments is somewhat less critical, it is preferred to utilize copolymers that do not require solubiUzing agents, as such compounds may disrupt or modify the HLB.
• the preferred copolymers of formula (I) above ate those wherein there is a predominance of EO to BO segments. That is, the variable "m" in formula (I) and formula (Ii) above is preferably greater than the variable
• the EO-BO block co-polymers will preferably have a ratio of EO to BO segments of from about 2:1 to about. 10:1, with a ratio of about 3:1 to about 6:1 being most preferred.
• the EO-BO block copolymers of the present invention may be prepared using synthetic methods known to those of skill in the art, for example, as described in Nace. V. M., J. Am. Oil Chem. Soc, Vol 73(1): 1-9, 1996; Yang et a!.. Macromolecules, Vol. 27:2371-2379. 1994; Yang et al. Langmuir. Vol. 11 :4703, 1995; Yu et a!.. Langmuir. Vol. 12:3404-3412. 1996; Chaibundit et al., Langmuir. Vol. 16:9645-9652. 2000; Bedells et al., J. Chem. Soc, Faraday Trans.. Vol.
• EO-BO block copolymers may also be prepared by the application or adaptation of known methods described in U.S. Patent Nos. 2.828,345 (Spriggs), and 2,174,761 (Schuette et al.). the entire contents of each of which are hereby incorporated into the present specification by reference. Additional synthetic procedures are taught by Keiets ⁇ n et al. (U.S. Patent Application Serial No. ⁇ 1/953654). the contents of which are herein incorporated by reference in its entirety.
• (he EO-BO block copolymers described above may be synthesized using a well defined polyethylene glycol (PEG) polymer by controlled addition of oxybutylene to the primary hydroxy! group of the PEG polymer.
• PEG polyethylene glycol
• the FX)-BO di-block copolymer (EO) ⁇ j(BO)Io may be prepared according to the following genera! reaction scheme:
• block chemistry structure may also be prepared, using techniques and methods readily available and well-known to those skilled in art.
• reaction process may be utilized for the preparation of tri- block copolymers of the form
• the E(I)-BO block copolymers of the present invention may also be functional ized with specific end groups for specific surface reactions to covatently bind the polymer to a surface or prepare a new polymer material.
• the BO-BO block copolymers that may be utilized in die present invention are not limited relative to structure or molecular weight, so !ong as the block copolymers are soluble in aqueous solutions and are non-toxic to ophthalmic tissue at concentrations on the order of those described herein.
• the term "galactomannan” refers to polysaccharides derived from the above natural gums or similar natural or synthetic gums containing mannose or galactose moieties, or both groups, as the main structural components.
• gaiactomannans typically derived from guar gum, locust bean gum and tara gum.
• the gaiactomannans of the present invention are obtainable from various commercial sources and via synthetic procedures known to those of skill in the art.
• the galactomannan is hydroxypropyl guar (HP-8A or HP-guar) obtained from Rhodia, Inc.
• Other galactomannan include, but are not limited to, native guar and hydroxypropy! guar galactomannan produced according to the processes of co- pending U.S. Patent. Application Serial Nos. 61/220,859 filed June 26, 2009, and 61/150,2 IS filed February 5.
• compositions of the present invention generally comprise galactomannan at a concentration of 0.01 to 2.0% w/v.
• Preferred compositions of the present, invention comprise galactomannan at a concentration of 0.05 to 0.25% w/v.
• compositions of the present invention optionally comprise one or more additional components.
• additional components include, but are not limited to, tonicity agents, preservatives, chelating agents, buffering agents, surfactants, co-solvents, and antioxidants.
• Other components used in certain embodiments are soiubilizing agents, stabilizing agents, comfort-enhancing agents, polymers, emollients, pH -adjusting agents and/or lubricants.
• compositions of the present invention including water, mixtures of water and water-miscible solvents, such as Cl- C?-alkanols, vegetable oils or mineral oils comprising from 0.5 to 5% non-toxic water-soluble polymers, natural products, such as alginates, pectins, tragacanth, karaya gum.
• xanthan gum carragecnin, agar and acacia
• starch derivatives such as starch acetate and hydroxypropyl starch
• oilier synthetic products such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, polyethylene oxide, preferably cross-linked polyacryiic acid, and mixtures of those products.
• compositions of the present invention may comprise compounds having antimicrobial or preservative properties.
• Suitable antimicrobial agents include, but are not limited to those generally used in contact lens care solutions or in other ophthalmic solutions such as poiyqu&temium-1, which is a polymeric quaternary ammonium compound; myristamidopropyl dimethylamine (“MAPDA"). which is a N,N-dialkyl N'-alkyl.
• the additional antimicrobial agents that may be utilized in the present invention also include the ar ⁇ mobiguanides described in U.S. Patent No. 6.664,294, the entire contents of which are hereby incorporated in the present specification by reference.
• the preferred additional antimicrobial agents are polyquaternium- 1 , MAPDA and the amino biguanide identified in U.S. Patent No. 6,664,29-i as "Compound Number 1 ".
• Suitable antioxidants include, but are not limited to, sulfites, ascorbates. hutylated hydroxyanisole (BHA) and butylated hydroxytol ⁇ ene (BHT).
• compositions of the present invention may comprise one or more surfactants.
• Surfactants utilized in the compositions of the present invention can be cationic anionic, nom ' onic or amphoteric.
• Preferred surfactants arc neutral or noninonic surfactants which may present in amounts up to 5 w/v%.
• Surfactants that may be used with certain embodiments of the present invention include, but are not limited to, polyethylene glycol ethers or esters of fatty acids, polyoxyethylene-polyoxyptopy ⁇ ene block copolymers of ethylene diamine (e.g..).
• poloxamines such as Tetronic 1304 or 1107), po ⁇ yoxypr ⁇ pylene-polyoxycthylene glycol nonionic block copolymers (e.g., poloxamers, such as Plutonic F- 127), and p-isooetylpolyethylen phenol formaldehyde polymers (e.g., Tyloxapol).
• suitable cosolvents include glycerin, propylene glycol and polyethylene glycol.
• Buffering agents which may be incorporated into compositions of the present invention include, but are not limited to. alkaline metal salts, such as potassium or sodium carbonates, acetates, borates, phosphates and citrates, and weak acids, such as acetic acids and boric acids.
• the preferred buffering agents are alkaline metal borates, such as sodium or potassium borates.
• Other pH-adjusting agents such as inorganic acids and bases, may also be utilized.
• hydrochloric acid or sodium hydroxide may be employed in concentrations suitable for ophthalmic compositions.
• the above-described buffering agents are generally present in amounts from about 0.1 to about 2.5 w/v%, preferably from about 0.5 to about 1.5 % w/v%.
• compositions of the present invention are preferably isotonic, or slightly hypotonic, and generally have an osmolality in the range of 210-320 m ⁇ sm/kg, and preferably have an osmolality in the range of 235-300 m ⁇ sm/kg. This may require a tonicity agent to bring the osmolality of the composition to the desired level.
• TonicUy-adjusting agents include, but are not limited to, sodium chloride, glycerm, sorbitoL or mannitol.
• disinfectants that may be used include, but are not limited to halamines. halogenated amino acids, bis-amines, and certain preservatives listed above.
• the amount of the disinfectant required to achieve the desired disinfection activity can be determined by persons skilled in the art. The concentration required to achieve the desired activity as a disinfectant while retaining acceptable safety and toxicity properties is referred to herein as "an effective amount”.
• An effective amount will possess antimicrobial activity sufficient to meet generally accepted standards for activity, such as EN ISO 14729:2001 Ophthalmic optics
• the pH of the compositions may be in an ophthalmic acceptable range of 3.0 to 8.0.
• Preferred ophthalmic compositions are prepared using a buffering system that maintains the composition at a pH of about 3.0 to a pH of about 8.0.
• compositions of the present invention are suitable for topical application to mammalian eyes.
• the composition may be a solution, a suspension, a get vvater-in-oil and oil-in-water emulsions, or an ointment.
• Preferred compositions for ophthalmic administration will be aqueous solution in the form of drops.
• aqueous typically denotes an aqueous composition wherein the excipient is >50%, more preferably >75% and in particular >90% by weight water.
• These drops may be delivered from a single dose ampoule which may preferably be .sterile and thus render bacteriostatic components of the composition unnecessary.
• the drops may be delivered from a multi-dose bottle which may preferably comprise a device which extracts preservative from the composition as it. is delivered, such devices being known in the art.
• the compositions of the present invention may comprise one or more tear substitutes. A variety of tear substitutes are known in the art.
• polymeric poiyols such as polyethylene glycol: cellulose esters such hydroxypropylmethyl cellulose, carboxy methylceliuiose sodium and hydroxy propylcellulose; dextrans such as dextran 70; vinyl polymers, such as polyvinyl alcohol; and carbomers, such as carbomer 934P, carbomer 941, carbomer 940 and carbomer 974P.
• Topical ophthalmic compositions of the present invention generally have a viscosity of 0.5-100 cps, preferably 0.5-50 cps, and most preferably 1-20 cps. This relatively low viscosity insures that the product is comfortable, does not cause blurring, and is easily processed during manufacturing, transfer and filling operations.
• compositions of the present invention can also be used to deliver a pharmaceutical agent to the eye.
• pharmaceutical agents include, but are not limited to anti-glaucoma agents, imii-angiogenesis agents; ami-infective agents; antiinflammatory agents: growth factors; immunosuppressant agents; and aiHi-allergic agents.
• Anti-glaucoma agents include, but are not limited to, beta-blockers, such as betaxolol and ievobetaxolol; carbonic anhydrase inhibitors, such as brinzoiamide and dorzolamide; prostaglandins, such as travoprost. bimatoprost.
• Anti-angiogenesis agents include, but are not limited to, anecortave acetate (RET AANE M . Alcon TM Laboratories, Inc. of Fort Worth. Tex.) and receptor tyrosine kinase inhibitors (RTKi).
• Antiinflammatory agents include, but arc not limited to, non-steroidal and steroidal anti- inflammatory agents, such as triamcinolone acttnide, suprofen. diclofenac, ketorolac, nepafenac, rimexofone. and tetrahydrocortisol.
• Growth factors include EGF or VEGF.
• Anti-allergic agents include, but are not limited to, olopatadine and epinas ⁇ ne, H1 and H4 receptor antagonists (such as those disclosed in WO 2010/030785 to Borchardt et al, herein incorporated by reference in its entirety).
• the oscillation stress sweep measures G' (elastic/storage modulus) and G' (viscous, loss modulus). From this information the linear viscoclastic region (LVR) can be determined.
• the LVR is a region In the stress sweep, obtained from G' where the solution holds its elasticity, G' over a range of stresses. A measure of relative elasticity, , is obtained from these experiments.
• the oscillation frequency sweep holds the stress constant within the LVR while measuring a range of frequencies. This measurement can determine G', (P and Um(S) as well.
• the osculation frequency sweep shows how well a solution maintains its structure. lnterfaciai rheoiogy experiments were conducted using an optica!
• OCA20 oscillating drop generator device
• OCA20 Dataphysics Instruments
• the drop suspended in a temperature and humidity controlled cell at the tip of a stainless steel needle of 1.65mm externa! diameter, was observed with a CCD camera
• the oscillating drop generator (C)DCi) technique characterizes the mechanical strength of the films formed by analyzing the drop shape at a set frequency over a range of amplitudes. The amplitude changes the volume and shape of the drop and therefore the surface area.
• Torque was set from 0.1 ⁇ Nr ⁇ to 100 ⁇ Nm
• TABl-ES 1 and 2 below detail compositions tested in the EO-BO interfacia! rheology and EO-BO/guar rheoiogy experiments, respectively. All compositions of TABLE 2 also comprise 1.0% boric acid, 0.35% NaCl, and 0.001% polyquaternium- 1. and have a pH of 7.5.
• FIGURE 1 shows the amplitude sweep for the EO-BO compositions of 5 TABLE 1.
• the graphs demonstrate that the elastic contribution at (he air-water interface tor these EO-BO compositions increases as the BO unit size increases from
• FIGURES 2a-2e show steady state slow curves for EO-BO and HP-Guar
• EO-BO block copolymer concentration increases.
• EO,i ⁇ BO*.u compositions have similar viscosity profiles compared to the composition containing only HP-guar.
• compositions have shear thinning profiles which are similar that of the composition containing only HP-guar, however, their viscosities are lower than the
• FIGURES 3a-3e show stress sweep curves for EO-BO and HP-Guar compositions of TABLE 2. The curves demonstrate that all compositions tested are viscous (G") dominant solutions with elasticity (G', structure).
• G viscous
• G' structure
• EO. «BOV ⁇ 0 compositions have a similar structure to the composition containing only HP-guar, with similar linear viscoelastic regions. compositions have some structure, hut have linear viscoeiastic regions that drop off rapidly as the shear rate increases.
• FKlURES 4a-4e show frequency sweep curves for and HP-Guar compositions of TABLE 2. compositions have a similar structure to the composition containing only HP-guar throughout the frequency sweep.
• compositions have some structure, which drops off rapidly at higher frequency.
• FIGURES 5a-5d show extensional rheology curves for the EO-BO and HP- guar compositions of TABLE 2.
• the curves demonstrate that compositions have longer break up times than the composition containing only HP- guar.
• compositions have similar break up times compared to the composition containing only HP-guar.
• compositions also have higher extensiona! viscosities relative to the composition containing only HP-guar.
• compositions have similar extensional viscosities relative to the composition containing only HP-guar.
• the effect of EO-BO compositions was seen in other ga ⁇ actomannans such as native guar. As shown in TABLE 3 below. EO-BO increased the break up times for compositions comprising both HP-guar and native guar.
• FIGURES 6a-6b show amplitude sweep and frequency sweep curves tor EO- BO and HP-guar compositions of TABLE 2.
• both EO 45 B0 1 1 and compositions are elastic dominant at the air- water interface.
• BO dominates the structure at the air-water interface at the tested concentrations compared to guar.
• compositions of the present invention are well suited for ophthalmic applications and particularly topical ophthalmic applications.
• EO-BO and guar compositions may provide additional tear film stability when used in dry eye compositions.
• compositions of the present invention were tested for their ability to (i) prevent deposition of lipids and proteins on silicon hydrogel lenses and (H) to clean lenses of lipid and protein deposits.
• TABLE 4 is a summary of the lenses tested, and TABLES 5 and 6 list compositions that were tested.
• FIGURES 7a and 7b summarize experiments examining the ability of EO-BO compositions of the present invention to prevent the uptake of a polar lipid (FJTC-DHPE, FIGURE 7a) and a non-polar lipid (NBD-cholesteroU FIGURE 7b) by the silicon hydrogcl lenses of TABLE 4.
• the results illustrate that the compositions (Lot 13990-23 A and 23C. TABLE 6) are particularly effective at preventing the uptake of the non-polar lipid by all lenses tested.
• FIGURE 8 shows a bar chart showing the amount remaining of a non-polar lipid (NBD-choiesterol) on the lenses of TABLE 4 after cleaning with various test compositions.
• the chart illustrates that a composition of the present invention
• FIGURES 9a - 9 ⁇ demonstrate that a composition of the present invention ( 14336-1 1C. TAB IJ ⁇ 5) is effective at cleaning various proteins (lysozyme. lactofemn, beta-iactoglobulin) from the tested lenses of TABLE 4.
• compositions of the present invention are effective lens cleaners and can prevent the uptake of non- polar lipids.
• the compositions are also particularly effective at removing non-polar lipid deposits from lenses.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Wood Science & Technology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Ophthalmology & Optometry (AREA)
• Molecular Biology (AREA)
• Inorganic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Emergency Medicine (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Eyeglasses (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (2)

Family

ID=43427630

Family Applications (1)

Country Status (15)

Cited By (2)

Families Citing this family (2)

Family Cites Families (77)

• 2010
  • 2010-07-06 TW TW099122147A patent/TWI547522B/zh active
  • 2010-07-07 MX MX2012000456A patent/MX2012000456A/es active IP Right Grant
  • 2010-07-07 BR BR112012000506A patent/BR112012000506A2/pt not_active IP Right Cessation
  • 2010-07-07 EP EP10732590.4A patent/EP2451463B1/en active Active
  • 2010-07-07 WO PCT/US2010/041218 patent/WO2011005864A2/en not_active Ceased
  • 2010-07-07 AU AU2010270628A patent/AU2010270628B2/en not_active Ceased
  • 2010-07-07 CA CA2767459A patent/CA2767459C/en active Active
  • 2010-07-07 RU RU2012103982/15A patent/RU2548789C2/ru active
  • 2010-07-07 AR ARP100102444A patent/AR077458A1/es unknown
  • 2010-07-07 KR KR1020127003060A patent/KR101246243B1/ko not_active Expired - Fee Related
  • 2010-07-07 JP JP2012519699A patent/JP5791600B2/ja active Active
  • 2010-07-07 US US12/831,890 patent/US9175249B2/en active Active
  • 2010-07-07 CN CN201080038179.XA patent/CN102548561B/zh active Active
• 2012
  • 2012-01-09 CL CL2012000061A patent/CL2012000061A1/es unknown
  • 2012-01-12 ZA ZA2012/00255A patent/ZA201200255B/en unknown

Also Published As

Similar Documents

Legal Events